Knee ligaments

Global Cruciate Ligament Repair Procedures Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, June 21, 2021
Physical therapy, Health, Musculoskeletal system, Knee ligaments, Anatomy, Medicine, Anterior cruciate ligament, Cruciate ligament, Knee, Orthopedic surgery, Ligament, Schenck classification, Tightrope CCL

The outbreak of COVID-19 worldwide showed an impact on the market studied as surgical procedures kept on hold in order to prevent the spread of the COVID-19 virus.

Key Points: 
  • The outbreak of COVID-19 worldwide showed an impact on the market studied as surgical procedures kept on hold in order to prevent the spread of the COVID-19 virus.
  • For instance, according to Thirunarayanan V, published in October 2020, outpatient orthopedic services decreased by 75% during this pandemic in India.
  • According to the study "Anterior Cruciate Ligament Knee Injuries" published in 2020, the anterior cruciate ligament (ACL) is frequently injured among athletes and trauma victims.
  • Therefore, the rising burden of injuries is expected to boost the market growth in coming years.

With Spring Training Around the Corner, ZetrOZ Systems' sam® Sport is the Ideal Solution for Injury Recovery Without Surgery

Retrieved on: 
Tuesday, March 16, 2021
Injuries, Musculoskeletal system, Overuse injuries, Organ systems, Soft tissue disorders, Knee ligaments, Musculoskeletal disorders, Sports injuries

sam Sport is an FDA-cleared bio regenerative, wearable medical device that helps reduce pain associated with tendon, ligament, and muscle injuries.

Key Points: 
  • sam Sport is an FDA-cleared bio regenerative, wearable medical device that helps reduce pain associated with tendon, ligament, and muscle injuries.
  • sameffectively treats over 35% of tendon, ligament, and muscle injuries without surgery, helping athletes at every level get relief from pain.
  • ZetrOZ Systems is an FDA cGMP and ISO 13585 medical technology company headquartered in the southern coastal region of Connecticut.
  • ZetrOZ Systems produced UltrOZ, samSport and samPro 2.0 to provide safe and effective treatment options for prevalent conditions such as arthritis.

Conformis, Inc. Announces Clearance in Australia for iTotal® PS, the Only Personalized, Posterior-Stabilized Total Knee Replacement System

Retrieved on: 
Monday, March 1, 2021
Surgery, Medical specialties, Prosthetics, Knee replacement, Surgical specialties, Knee ligaments, Ligaments, Knee, Posterior cruciate ligament, Cruciate ligament, Cruciate

iTotal PS implants are specifically designed to restore the natural shape of each patients knee, and to avoid overhang, rotation, and sizing compromises associated with pain after surgery.

Key Points: 
  • iTotal PS implants are specifically designed to restore the natural shape of each patients knee, and to avoid overhang, rotation, and sizing compromises associated with pain after surgery.
  • Primary total knee implants are designed to either retain the patients own posterior cruciate ligament (cruciate-retaining, or CR), or substitute for it (posterior-stabilized, or PS).
  • Receiving clearance for our iTotal PS product in Australia will allow us to offer a best-in-class, patient-specific solution to relieve patients chronic knee joint pain, said Mark Augusti, President and CEO.
  • HCF, Australias largest nonprofit health insurer, reports that more than 50,000 knee replacement procedures are performed in Australia each year.

Biorez Preclinical Results to be Presented at the ORS 2021 Annual Meeting

Retrieved on: 
Friday, February 12, 2021
Medical specialties, Surgery, Orthopedics, Shoulder, Knee ligaments, Orthopaedic Research Society, Orthopedic surgery, Patellar ligament, Rotator cuff

NEW HAVEN, Conn., Feb. 12, 2021 /PRNewswire-PRWeb/ --Biorez Inc., a New Haven start-up advancing tendon and ligament repair, announced that the results of two recently concluded preclinical studies of its BioBrace Technology will be presented virtually at the Orthopaedic Research Society (ORS) 2021 Annual Meeting to be held February 12-16, 2021.

Key Points: 
  • NEW HAVEN, Conn., Feb. 12, 2021 /PRNewswire-PRWeb/ --Biorez Inc., a New Haven start-up advancing tendon and ligament repair, announced that the results of two recently concluded preclinical studies of its BioBrace Technology will be presented virtually at the Orthopaedic Research Society (ORS) 2021 Annual Meeting to be held February 12-16, 2021.
  • "The BioBrace scaffold is an exciting and new soft tissue implant technology that exceeded my expectations in our preclinical evaluations in both rotator cuff and patellar tendon defect models.
  • We are excited and honored to participate in the Orthopedic Research Society's annual meeting, and it marks the second and third time in three months that our preclinical work has been featured during prestigious annual meetings."
  • Biorez is a New Haven-based medical device start-up focused on advancing the healing of soft tissues using its proprietary BioBrace technology.

Arthrex Launches First FDA-Cleared ACL Primary Repair Kit

Retrieved on: 
Friday, December 18, 2020
Musculoskeletal system, Knee ligaments, Medical specialties, Surgery, Anterior cruciate ligament reconstruction, Anterior cruciate ligament injury, Anterior cruciate ligament, Orthopedic surgery, Ligament, Cruciate ligament, ACL, Reinhold Schmieding

It is the first and only FDA-cleared kit for the primary repair of anterior cruciate ligament (ACL) tears.

Key Points: 
  • It is the first and only FDA-cleared kit for the primary repair of anterior cruciate ligament (ACL) tears.
  • "Arthrex is defining the future for ACL treatment as the first orthopedic company to develop and market a kit specifically for ACL repair," said President and Founder Reinhold Schmieding.
  • ACL primary repair with the SwiveLock ACL Repair Kit involves reattaching a torn ACL utilizing SwiveLock anchors and high-strength FiberWire and TigerWire sutures.
  • While primary 'repair' will not replace reconstruction for all cases, the procedure, utilizing the SwiveLock ACL Repair Kit, is valuable tool to help surgeons treat their patients better."

Miach Orthopaedics’ BEAR® Implant Granted FDA De Novo Approval for Treatment of ACL Tears

Retrieved on: 
Thursday, December 17, 2020
FDA, Surgery, Medical devices, Health, Physical therapy, Medicine, Clinical medicine, Knee ligaments, Medical specialties, Prosthetics, Anterior cruciate ligament reconstruction, Anterior cruciate ligament injury, Implant, The BEAR® Implant, Miach Orthopaedics, Inc.

The BEAR Implant is the first medical technology to clinically demonstrate that it enables healing or restoration of the patients torn ACL.

Key Points: 
  • The BEAR Implant is the first medical technology to clinically demonstrate that it enables healing or restoration of the patients torn ACL.
  • As the ACL heals, the BEAR Implant is absorbed by the body, within approximately eight weeks.
  • Miach Orthopaedics new Bridge-Enhanced ACL Repair (BEAR) Implant is a proprietary bio-engineered implant used to facilitate healing of the torn ACL.
  • The companys initial focus is the Bridge-Enhanced ACL Repair (BEAR) Implant, which represents a paradigm shift in the treatment of ACL tears from reconstruction to restoration.

AlloSource® Names Tendon And Ligament Portfolio Under New Brand AlloConnex™

Retrieved on: 
Thursday, July 23, 2020
Musculoskeletal system, Muscular system, Medical Subject Headings, Skeletal system, Soft tissue, Knee ligaments, Peroneus longus, Tibia, Ligament, Patellar ligament, Semitendinosus muscle, Allotransplantation

CENTENNIAL, Colo., July 23, 2020 /PRNewswire/ --AlloSource, one of the largest allograft providers in the U.S., creating innovative cellular and tissue allografts to help surgeons heal their patients, today announced it is naming its tendon and ligament portfolio under the new brand AlloConnex.

Key Points: 
  • CENTENNIAL, Colo., July 23, 2020 /PRNewswire/ --AlloSource, one of the largest allograft providers in the U.S., creating innovative cellular and tissue allografts to help surgeons heal their patients, today announced it is naming its tendon and ligament portfolio under the new brand AlloConnex.
  • "AlloConnex aligns with AlloSource's other brands, while conveying the physical connection of tendon and ligament transplantation through the skilled hands of a surgeon."
  • The AlloConnex tendon and ligament portfolio supports a multitude of procedures surgeons perform to connect patients back to their active lifestyles.AlloSource's tendon supply includes single strand, double strand, double bundle and pre-shaped configurations.Specific allografts in the AlloConnex portfolio include the Achilles, anterior tibialis, gracilis, peroneus longus, posterior tibialis and semitendinosus tendons, as well as patellar ligaments.
  • The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit allosource.org .

Study Finds Enhanced Milestone-Based Rehabilitation After ACL Surgery Offers Cost Benefits for Insurers

Retrieved on: 
Monday, June 22, 2020
Knee ligaments, Anterior cruciate ligament reconstruction, Knee, Surgery

The findings address a common but counterproductive trade-off in orthopedic surgery: Health insurers typically stop paying for rehabilitation before patients are fully recovered and able to return to full physical activity.

Key Points: 
  • The findings address a common but counterproductive trade-off in orthopedic surgery: Health insurers typically stop paying for rehabilitation before patients are fully recovered and able to return to full physical activity.
  • "The purpose of this study was to ask, 'Is an enhanced postoperative rehabilitation approach cost-effective for insurers?'
  • These savings occur because they pay for fewer repeat surgeries due to re-tearing or tearing the ACL of the other knee.
  • For the study, Dr. Fabricant and his colleagues used nationally available data about the costs of rehabilitation and ACL surgery to develop a cost-benefit model for enhanced rehab.

Modified ACL Reconstruction Technique in High-Risk Adolescent Athletes Shows Promising Results

Retrieved on: 
Monday, June 1, 2020
Knee ligaments, Clinical medicine, Anterior cruciate ligament reconstruction, Anterior cruciate ligament injury, Knee, Surgery

These results, from 28 patients under age 20, are the first to emerge from a larger study currently in progress.

Key Points: 
  • These results, from 28 patients under age 20, are the first to emerge from a larger study currently in progress.
  • The goals of ACL surgery are to reconstruct a torn ACL to help stabilize the knee and to allow athletes to return to their former level of sports activity after recovery.
  • The additional surgical technique is called a modified Lemaire IT band tenodesis, named after Marcel Lemaire, a surgeon in France who originally described it in 1975.
  • "At HSS, we're proud to be one of the first groups to use this technique in high-risk teenage athletes in North America."

Human Growth Hormone May Prevent Loss of Muscle Strength after Anterior Cruciate Ligament Reconstruction

Retrieved on: 
Tuesday, May 26, 2020
Growth hormones, Medicine, Musculoskeletal system, RTT, Knee ligaments, Hormones, Eli Lilly and Company, Genentech, Growth hormone therapy, Anterior cruciate ligament, Growth hormone, Osteoarthritis

NEW YORK, May 26, 2020 /PRNewswire/ --Human growth hormone (HGH) may prevent the loss of muscle strength after anterior cruciate ligament (ACL) reconstruction, according to results from a pilot study conducted by investigators at Hospital for Special Surgery (HSS) in collaboration with colleagues at the University of Michigan.

Key Points: 
  • NEW YORK, May 26, 2020 /PRNewswire/ --Human growth hormone (HGH) may prevent the loss of muscle strength after anterior cruciate ligament (ACL) reconstruction, according to results from a pilot study conducted by investigators at Hospital for Special Surgery (HSS) in collaboration with colleagues at the University of Michigan.
  • The drug is available only by prescription for treating growth hormone deficiency syndromes and cannot be used off-label without FDA approval.
  • "We think using human growth hormone to prevent loss of muscle strength after ACL reconstruction would meet the therapeutic use exception guidelines," says Dr. Mendias.
  • "Preventing the loss of strength after ACL reconstruction with human growth hormone may help prevent the development or lessen the severity of osteoarthritis in the future," says Dr. Mendias.